Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.20.4
Stockholders' Equity (Tables)
 6 Months Ended
Jan. 31, 2021
Stockholders' Equity Note [Abstract]  
Schedule of amounts of share-based compensation expense
    Three months ended
January 31,		     Six months ended
January 31,		  
    2021     2020     2021     2020  
Stock options   $ 175     $ 301     $ 341     $ 518  
Restricted stock     1       1       2       3  
    $ 176     $ 302     $ 343     $ 521  
Schedule of share-based payment arrangement
    Three months ended
January 31,		     Six months ended
January 31,		  
    2021     2020     2021     2020  
Selling, general and administrative   $ 162     $ 302     $ 316     $ 521  
Cost of revenues     14       -         27       -    
    $ 176     $ 302     $ 343     $ 521  
Schedule of stock option activity
    Options     Weighted
Average
Exercise
Price		     Weighted
Average
Remaining
Contractual
Term		     Aggregate
Intrinsic
Value (000s)		  
Outstanding at July 31, 2020       2,636,496     $ 4.05                  
Awarded     543,104     $ 2.57                  
Exercised     —                     $    
Expired or forfeited     (408,539 )   $ 2.91                  
Outstanding at end of period     2,771,061     $ 3.80       3.0 years     $ 114  
Exercisable at end of period     1,566,259     $              1.9 years     $    
Schedule of nonvested performance-based units activity
 Grant Date   Total Grant     Forfeitures     Outstanding    

Fair Market Value

At Grant Date (000s)

  
10/15/2018     32,000       (6,000 )     26,000     $ 107  
10/15/2019     80,500       (14,500 )     66,000     $ 222  
10/19/2020     98,600       -         98,600     $ 207